Cytokine release inhibitory drug 3 (CRID3) (200 mg/kg/, dosed twice a day by oral gavage), a selective inhibitor of the NLRP3 inflammasome, reversed the TAC-induced pyroptosis cascade. The gene discussed is NLRP3; the disease is persistent truncus arteriosus.